Cargando…
Asymmetric dimethylarginine (ADMA) accelerates renal cell fibrosis under high glucose condition through NOX4/ROS/ERK signaling pathway
We previously reported that the circulatory level of Asymmetric dimethylarginine (ADMA), an endogenous competitive inhibitor of nitric oxide synthase, was increased in diabetic kidney disease patients. However, the mechanism and the role of ADMA in diabetic kidney injury remain unclear. Hence, our p...
Autores principales: | Jayachandran, Isaivani, Sundararajan, Saravanakumar, Venkatesan, Saravanakumar, Paadukaana, Sairaj, Balasubramanyam, Muthuswamy, Mohan, Viswanathan, Manickam, Nagaraj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525240/ https://www.ncbi.nlm.nih.gov/pubmed/32994511 http://dx.doi.org/10.1038/s41598-020-72943-2 |
Ejemplares similares
-
Metformin Reduces the Progression of Atherogenesis by Regulating the Sestrin2-mTOR Pathway in Obese and Diabetic Rats
por: Sundararajan, Saravanakumar, et al.
Publicado: (2023) -
Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA)
por: Tain, You-Lin, et al.
Publicado: (2017) -
Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes
por: Tsikas, Dimitrios, et al.
Publicado: (2018) -
Asymmetric Dimethylarginine (ADMA) and Endothelial Dysfunction: Implications for Atherogenesis
por: Landim, Maurício Batista Paes, et al.
Publicado: (2009) -
The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
por: Sibal, Latika, et al.
Publicado: (2010)